Contemporary Management of HIV 2021

Download All
Gain expert insights on the latest data supporting contemporary HIV prevention and HIV treatment across settings, including patients who are newly diagnosed, virologically suppressed, or experiencing virologic failure with resistance, along with new and emerging ART strategies.
Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Roger Bedimo, MD, MS, FACP
Michelle S. Cespedes, MD, MS
Eric S. Daar, MD
person default
Geeta Gupta, MD
Jason Halperin, MD, MPH
W. David Hardy, MD
Gregory Huhn, MD, MPHTM
Daniel R. Kuritzkes, MD
David Malebranche, MD, MPH
Paul E. Sax, MD
Renslow Sherer, MD
William R. Short, MD, MPH, AAHIVS
Shobha Swaminathan, MD
Babafemi Taiwo, MBBS
David A. Wohl, MD

New Data From IAS 2021

Listen as expert faculty discuss key studies influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic, metabolic, and safety outcomes of 2DR with DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive and heavily treatment–experienced PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.

Eric S. Daar, MD Shobha Swaminathan, MD Released: September 8, 2021

Listen as expert faculty discuss key studies influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic, metabolic, and safety outcomes of 2DR with DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive and heavily treatment–experienced PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.

Eric S. Daar, MD Shobha Swaminathan, MD Released: September 14, 2021

Download this expert-authored slideset to review the most clinically relevant new data presented at IAS 2021 covering a wide range of HIV management topics, including HIV and COVID-19 outcomes, 2-drug ART, long-acting injectable ART, investigational ART, and TB treatment options.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: September 13, 2021

New Data From CROI 2021

Watch this dynamic video module in which CCO’s expert faculty, Drs. Eric Daar and Renslow Sherer, present and discuss with one another some of the most clinically relevant new data presented at CROI 2021, including results from studies on HIV PrEP strategies, COVID-19 outcomes among PWH, ART during pregnancy/postpartum period, long-term use of current ART, and novel ART strategies in late-phase development.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD Renslow Sherer, MD
Released: May 10, 2021

Download this expert-authored slideset to review the most clinically relevant new data presented at CROI 2021 covering a wide range of HIV management topics, including HIV PrEP strategies; ART in pregnancy, the postpartum period, and adolescence; current and investigational ART; and coinfections.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: April 9, 2021

Listen to expert insights from Daniel R. Kuritzkes, MD, and Michelle S. Cespedes, MD, MS, on updates from virtual CROI 2021, including new data on first-line ART and results from the ATLAS 2M and CAPELLA trials.

Michelle S. Cespedes, MD, MS Daniel R. Kuritzkes, MD Released: May 18, 2021

ART for Complex Cases

Gain expert insights on treatment strategies for complex HIV cases; topics include managing ART in heavily treatment-experienced patients, modifying ART in patients with underlying ARV resistance, and considerations for first-line ART selection in patients with obesity.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD Jason Halperin, MD, MPH
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 8, 2020 Expired: December 7, 2021

Download this expert-authored slideset to review treatment strategies for complex HIV cases; topics include managing heavily treatment-experienced patients, modifying ART in patients with underlying ARV resistance, and considerations for first-line ART selection in patients with obesity.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD
Released: September 1, 2020

Emerging Approaches to Optimize ART

Gain expert insights on important clinical questions related to first-line ART, switch strategies for patients with virologic suppression, and use of antiretroviral drugs to prevent HIV infection, with an emphasis on the role of new and emerging strategies.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD Paul E. Sax, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 30, 2020 Expired: December 29, 2021

Download this expert-authored slideset to consider important clinical questions related to first-line ART, long-acting antiretroviral drugs, and 2-drug regimens for ART, with an emphasis on the role of new and emerging strategies.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
David A. Wohl, MD
Released: March 17, 2021

Listen as expert faculty consider important clinical questions related to rapid ART initiation, long-acting antiretroviral drugs, and 2-drug regimens for ART, with an emphasis on the role of new and emerging strategies in the treatment of HIV.

Paul E. Sax, MD Released: August 25, 2021

Frontiers in HIV Prevention

Download this expert-authored slideset reviewing the latest data on HIV prevention, including PrEP uptake, current PrEP options, and next-generation PrEP options.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Gregory Huhn, MD, MPHTM
Released: March 3, 2021

Listen to expert insights from W. David Hardy, MD, on current options for pre-exposure prophylaxis and exciting new data on next-generation HIV prevention.

W. David Hardy, MD Released: June 2, 2021

Are you abreast of what is in the pipeline for HIV prevention? Listen to expert discussion by Joseph J. Eron, Jr., MD, on 4 investigational agents for HIV prevention.

Joseph J. Eron, Jr., MD
Program Director
Released: June 30, 2021

Heavily Treatment-Experienced Patients

Gain expert insights on treatment strategies for heavily treatment–experienced patients with HIV. Topics include assessment of virologic failure, current treatment options for patients with multiclass drug resistance, and guidance on selecting the next line of therapy for patients experiencing virologic failure due to resistance.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Roger Bedimo, MD, MS, FACP Eric S. Daar, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: December 22, 2020 Expired: December 21, 2021

Download this expert-authored slideset to review guidelines and key data on assessing virologic failure, current management options for patients with multiclass drug resistance experiencing treatment failure, and considerations for switching ART in patients with underlying resistance.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD
Released: March 3, 2021

Listen as expert faculty consider important clinical questions related to heavily treatment–experienced patients with HIV, including managing virologic failure and switching ART in the presence of underlying drug resistance.

person default Geeta Gupta, MD Released: September 1, 2021

Listen as expert faculty consider important clinical questions related to heavily treatment–experienced patients with HIV, including managing virologic failure and switching ART in the presence of underlying drug resistance.

person default Geeta Gupta, MD Released: September 2, 2021

Listen as expert faculty consider important clinical questions related to heavily treatment–experienced patients with HIV, including managing virologic failure and switching ART in the presence of underlying drug resistance.

person default Geeta Gupta, MD Released: September 7, 2021

Individualizing First line ART

Listen to expert insights from William R. Short, MD, MPH, AAHIVS, on optimizing initial antiretroviral therapy for treatment-naive patients with HIV.

William R. Short, MD, MPH, AAHIVS Released: May 7, 2021

Listen to expert insights from David A. Wohl, MD, on initiating antiretroviral therapy for a treatment-naive patient with HIV, HBV, and obesity.

David A. Wohl, MD Released: June 15, 2021

Download this expert-authored slideset to review national guidelines, key study data, and individual considerations for optimizing the use of current ART regimens as initial HIV treatment and in switch strategies for patients with viral suppression who require a change in therapy.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Babafemi Taiwo, MBBS
Released: July 6, 2020

Download this expert-authored slideset to review national guidelines, key study data, and individual considerations for individualizing first-line ART regimens to treat HIV.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: February 4, 2021

Modifying ART in Virologically Suppressed Patients

Download this expert-authored slideset to review guidelines and key data on assessing virologic failure, current management options for patients with multiclass drug resistance experiencing treatment failure, and considerations for switching ART in patients with underlying resistance.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Paul E. Sax, MD
Released: March 2, 2021

Review guidelines and key data on modifying ART in virologically suppressed patients, including switching ART to decrease pill burden and avoid comorbidities, switching to a long-acting injectable, and simplifying ART in the context of known multidrug resistance.

David Malebranche, MD, MPH Released: August 25, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue